MedTrace Logo

PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF

NCT06683612 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-08-06

No results posted yet for this study

Summary

This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF). The purpose of this study is to find out how much of the study drug gets into the brain and lung, and what the side effects and blood levels of the study drug are in healthy volunteers and patients.

Participants will:

* Take a single dose of the study drug
* Give many samples of blood and urine
* Have multiple PET scans

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)
  • Idiopathic Pulmonary Fibrosis
  • Multiple Sclerosis
  • Multiple Sclerosis, MS
  • Multiple Sclerosis, Primary Progressive
  • Multiple Sclerosis, Progressive
  • Multiple Sclerosis, Secondary Progressive
  • Healthy
  • Healthy Volunteers

Interventions

DRUG

PIPE-791

Subjects will receive a single oral dose of PIPE-791.

Sponsors & Collaborators

  • Contineum Therapeutics

    lead INDUSTRY

Principal Investigators

  • Stephen Huhn, MD · Contineum Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-09
Primary Completion
2025-06-04
Completion
2025-06-12

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06683612 on ClinicalTrials.gov